Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC).-Reference-Cited by-同舟云学术

Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC).

Published:2014-05-20 Issue:15_suppl Volume:32 Page:8001-8001
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Camidge D. Ross¹,Ou Sai-Hong Ignatius²,Shapiro Geoffrey³,Otterson Gregory Alan⁴,Villaruz Liza Cosca⁵,Villalona-Calero Miguel Angel⁶,Iafrate A. John⁷,Varella-Garcia Marileila⁸,Dacic Sanja⁹,Cardarella Stephanie³,Zhao Weiqiang⁶,Tye Lesley¹⁰,Stephenson Patricia¹¹,Wilner Keith D.¹⁰,James Leonard Philip¹⁰,Socinski Mark A.¹²

Affiliation:

1. University of Colorado Cancer Center, Aurora, CO

2. Chao Family Comprehensive Cancer Center, Orange, CA

3. Dana-Farber Cancer Institute, Boston, MA

4. Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH

5. University of Pittsburgh Cancer Institute, Pittsburgh, PA

6. Ohio State University Wexner Medical Center, Columbus, OH

7. Massachusetts General Hospital, Boston, MA

8. University of Colorado School of Medicine, Aurora, CO

9. University of Pittsburgh Medical Center, Pittsburgh, PA

10. Pfizer Oncology, La Jolla, CA

11. Rho, Inc., Chapel Hill, NC